IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. The presentations highlight significant advancements in the company's proprietary artificial intelligence platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings.
"We are excited to share our latest AI innovations at AAIC 2025, which underscore IGC's commitment to transforming Alzheimer's care and research," said Ram Mukunda, CEO of IGC Pharma. "Our cutting-edge deep learning techniques are designed to expand access to earlier diagnosis and accelerate the discovery of effective therapeutics by leveraging diverse, real-world datasets."
Revolutionary Cognitive Assessment Platform
IGC's first poster presentation (Number: 108631) introduces MINT-AD, a groundbreaking platform that demonstrates the use of large language models to accurately predict Mini Mental State Exam (MMSE) and Community Screening Instrument for Dementia (CSI-D) cognitive scores. The innovation lies in the platform's ability to make these predictions using socioeconomic data alone, without requiring brain scan or blood biomarker data.
This approach offers a highly scalable and accessible solution that could support clinicians in predicting cognitive decline trajectories and guiding early interventions, particularly valuable in settings where advanced diagnostic tools are not readily available.
AI-Driven Drug Discovery Pipeline
The second poster (Number: 108629) details IGC's hybrid in-silico and in-vitro pipeline, which utilizes AI-powered screening models to rapidly identify and optimize interactions between proprietary molecules and Alzheimer's-relevant targets, including GLP-1 and CB1 receptors. The results demonstrate strong predictive capabilities, showing significant promise for accelerating future in vitro validation and compound optimization efforts in Alzheimer's disease discovery.
Comprehensive Alzheimer's Portfolio
IGC Pharma operates as a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. The company's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The pipeline also includes TGR-63, which targets amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions.
The company integrates AI across multiple aspects of drug development to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma positions itself as advancing breakthrough therapies in the Alzheimer's space.
Mukunda emphasized that showcasing this research at the AAIC represents "a pivotal step as we establish IGC as a leader in applying AI to precision medicine in Alzheimer's, strengthening our scientific foundation and streamlining drug development."
